184 related articles for article (PubMed ID: 26437226)
1. Identification of novel, in vivo active Chk1 inhibitors utilizing structure guided drug design.
Massey AJ; Stokes S; Browne H; Foloppe N; Fiumana A; Scrace S; Fallowfield M; Bedford S; Webb P; Baker L; Christie M; Drysdale MJ; Wood M
Oncotarget; 2015 Nov; 6(34):35797-812. PubMed ID: 26437226
[TBL] [Abstract][Full Text] [Related]
2. The preclinical pharmacology and therapeutic activity of the novel CHK1 inhibitor SAR-020106.
Walton MI; Eve PD; Hayes A; Valenti M; De Haven Brandon A; Box G; Boxall KJ; Aherne GW; Eccles SA; Raynaud FI; Williams DH; Reader JC; Collins I; Garrett MD
Mol Cancer Ther; 2010 Jan; 9(1):89-100. PubMed ID: 20053762
[TBL] [Abstract][Full Text] [Related]
3. Chk1 inhibition as a novel therapeutic strategy for treating triple-negative breast and ovarian cancers.
Bryant C; Rawlinson R; Massey AJ
BMC Cancer; 2014 Aug; 14():570. PubMed ID: 25104095
[TBL] [Abstract][Full Text] [Related]
4. Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models.
Ma CX; Cai S; Li S; Ryan CE; Guo Z; Schaiff WT; Lin L; Hoog J; Goiffon RJ; Prat A; Aft RL; Ellis MJ; Piwnica-Worms H
J Clin Invest; 2012 Apr; 122(4):1541-52. PubMed ID: 22446188
[TBL] [Abstract][Full Text] [Related]
5. The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eµ-MYC driven B-cell lymphoma.
Walton MI; Eve PD; Hayes A; Henley AT; Valenti MR; De Haven Brandon AK; Box G; Boxall KJ; Tall M; Swales K; Matthews TP; McHardy T; Lainchbury M; Osborne J; Hunter JE; Perkins ND; Aherne GW; Reader JC; Raynaud FI; Eccles SA; Collins I; Garrett MD
Oncotarget; 2016 Jan; 7(3):2329-42. PubMed ID: 26295308
[TBL] [Abstract][Full Text] [Related]
6. γH2AX and Chk1 phosphorylation as predictive pharmacodynamic biomarkers of Chk1 inhibitor-chemotherapy combination treatments.
Rawlinson R; Massey AJ
BMC Cancer; 2014 Jul; 14():483. PubMed ID: 24996846
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of Chk1 with the small molecule inhibitor V158411 induces DNA damage and cell death in an unperturbed S-phase.
Wayne J; Brooks T; Massey AJ
Oncotarget; 2016 Dec; 7(51):85033-85048. PubMed ID: 27829224
[TBL] [Abstract][Full Text] [Related]
8. Identification of preferred chemotherapeutics for combining with a CHK1 inhibitor.
Xiao Y; Ramiscal J; Kowanetz K; Del Nagro C; Malek S; Evangelista M; Blackwood E; Jackson PK; O'Brien T
Mol Cancer Ther; 2013 Nov; 12(11):2285-95. PubMed ID: 24038068
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of ATR-dependent feedback activation of Chk1 sensitises cancer cells to Chk1 inhibitor monotherapy.
Massey AJ
Cancer Lett; 2016 Dec; 383(1):41-52. PubMed ID: 27693461
[TBL] [Abstract][Full Text] [Related]
10. mTORC1 and DNA-PKcs as novel molecular determinants of sensitivity to Chk1 inhibition.
Massey AJ; Stephens P; Rawlinson R; McGurk L; Plummer R; Curtin NJ
Mol Oncol; 2016 Jan; 10(1):101-12. PubMed ID: 26471831
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of the checkpoint kinase Chk1 induces DNA damage and cell death in human Leukemia and Lymphoma cells.
Bryant C; Scriven K; Massey AJ
Mol Cancer; 2014 Jun; 13():147. PubMed ID: 24913641
[TBL] [Abstract][Full Text] [Related]
12. Selective Chk1 inhibitors differentially sensitize p53-deficient cancer cells to cancer therapeutics.
Chen Z; Xiao Z; Gu WZ; Xue J; Bui MH; Kovar P; Li G; Wang G; Tao ZF; Tong Y; Lin NH; Sham HL; Wang JY; Sowin TJ; Rosenberg SH; Zhang H
Int J Cancer; 2006 Dec; 119(12):2784-94. PubMed ID: 17019715
[TBL] [Abstract][Full Text] [Related]
13. Enhancement of hypoxia-activated prodrug TH-302 anti-tumor activity by Chk1 inhibition.
Meng F; Bhupathi D; Sun JD; Liu Q; Ahluwalia D; Wang Y; Matteucci MD; Hart CP
BMC Cancer; 2015 May; 15():422. PubMed ID: 25994202
[TBL] [Abstract][Full Text] [Related]
14. Discovery of checkpoint kinase inhibitor (S)-5-(3-fluorophenyl)-N-(piperidin-3-yl)-3-ureidothiophene-2-carboxamide (AZD7762) by structure-based design and optimization of thiophenecarboxamide ureas.
Oza V; Ashwell S; Almeida L; Brassil P; Breed J; Deng C; Gero T; Grondine M; Horn C; Ioannidis S; Liu D; Lyne P; Newcombe N; Pass M; Read J; Ready S; Rowsell S; Su M; Toader D; Vasbinder M; Yu D; Yu Y; Xue Y; Zabludoff S; Janetka J
J Med Chem; 2012 Jun; 55(11):5130-42. PubMed ID: 22551018
[TBL] [Abstract][Full Text] [Related]
15. Preclinical development of the novel Chk1 inhibitor SCH900776 in combination with DNA-damaging agents and antimetabolites.
Montano R; Chung I; Garner KM; Parry D; Eastman A
Mol Cancer Ther; 2012 Feb; 11(2):427-38. PubMed ID: 22203733
[TBL] [Abstract][Full Text] [Related]
16. CHIR-124, a novel potent inhibitor of Chk1, potentiates the cytotoxicity of topoisomerase I poisons in vitro and in vivo.
Tse AN; Rendahl KG; Sheikh T; Cheema H; Aardalen K; Embry M; Ma S; Moler EJ; Ni ZJ; Lopes de Menezes DE; Hibner B; Gesner TG; Schwartz GK
Clin Cancer Res; 2007 Jan; 13(2 Pt 1):591-602. PubMed ID: 17255282
[TBL] [Abstract][Full Text] [Related]
17. Elimination of hepatic metastases of colon cancer cells via p53-independent cross-talk between irinotecan and Apo2 ligand/TRAIL.
Ravi R; Jain AJ; Schulick RD; Pham V; Prouser TS; Allen H; Mayer EG; Yu H; Pardoll DM; Ashkenazi A; Bedi A
Cancer Res; 2004 Dec; 64(24):9105-14. PubMed ID: 15604280
[TBL] [Abstract][Full Text] [Related]
18. LY2603618, a selective CHK1 inhibitor, enhances the anti-tumor effect of gemcitabine in xenograft tumor models.
Barnard D; Diaz HB; Burke T; Donoho G; Beckmann R; Jones B; Barda D; King C; Marshall M
Invest New Drugs; 2016 Feb; 34(1):49-60. PubMed ID: 26612134
[TBL] [Abstract][Full Text] [Related]
19. Targeting the replication checkpoint using SCH 900776, a potent and functionally selective CHK1 inhibitor identified via high content screening.
Guzi TJ; Paruch K; Dwyer MP; Labroli M; Shanahan F; Davis N; Taricani L; Wiswell D; Seghezzi W; Penaflor E; Bhagwat B; Wang W; Gu D; Hsieh Y; Lee S; Liu M; Parry D
Mol Cancer Ther; 2011 Apr; 10(4):591-602. PubMed ID: 21321066
[TBL] [Abstract][Full Text] [Related]
20. The histone deacetylase inhibitor PXD101 increases the efficacy of irinotecan in in vitro and in vivo colon cancer models.
Na YS; Jung KA; Kim SM; Hong YS; Ryu MH; Jang SJ; Moon DH; Cho DH; Kim JC; Lee JS; Kim TW
Cancer Chemother Pharmacol; 2011 Aug; 68(2):389-98. PubMed ID: 21046105
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
